OBN Weekly Ophthalmology News Update

1. Merit Acquires Ocular Services On Demand (OSOD) to Strengthen Ophthalmic Drug Development

Merit has announced the acquisition of Ocular Services On Demand (OSOD), a move aimed at bolstering its capabilities in early-stage ophthalmic drug development.

OSOD specializes in providing comprehensive ophthalmic research services, including preclinical and clinical development support for novel therapies.

By integrating OSOD’s expertise, Merit is expanding its ability to support companies developing innovative treatments for retinal diseases, glaucoma, and other ophthalmic conditions. This acquisition strengthens Merit’s position in the ophthalmic drug development space, allowing it to offer a broader range of services, from early research to regulatory approvals. As the demand for cutting-edge ophthalmic therapies grows, this acquisition ensures a more streamlined path from research to market.

?? What does this mean for future drug development? Find out here

2. Outlook Therapeutics Presents Results from NORSE EIGHT Trial

Outlook Therapeutics has shared new findings from its NORSE EIGHT trial, evaluating the efficacy and safety of ONS-5010, an investigational ophthalmic formulation of bevacizumab for wet AMD.

The results demonstrate a strong safety profile and consistent treatment effects, reinforcing its potential as an alternative to off-label bevacizumab use.

ONS-5010 aims to address the need for an FDA-approved ophthalmic bevacizumab formulation, reducing reliance on repackaged IV bevacizumab. The NORSE EIGHT study confirmed stable vision outcomes and safety across patient groups, supporting the therapy’s potential regulatory approval. If approved, ONS-5010 could bring a standardized, cost-effective anti-VEGF treatment to ophthalmology.

?? How could this impact wet AMD treatment? Read more

3. NeurEye Research Team Leads AI Innovation in Ophthalmology

A research team at NeurEye is making significant progress in AI-powered ophthalmology solutions. Their latest advancements focus on using deep learning to improve early detection of retinal diseases, including diabetic retinopathy and glaucoma.

NeurEye’s AI models analyze vast datasets of retinal scans, providing fast and highly accurate assessments for disease detection. By automating early diagnosis, this technology could improve screening efficiency, reduce the burden on specialists, and enhance patient outcomes. AI-driven ophthalmic diagnostics are expected to play a critical role in the future of preventive eye care.

??How is AI shaping the future of eye care? Explore the research

4. Norlase Secures FDA 510(k) Clearance and CE Mark for LYNX

Norlase has received both FDA 510(k) clearance and CE Mark approval for its LYNX laser system, a portable and highly efficient laser therapy device for retinal diseases.

The system is designed to enhance treatment flexibility while maintaining high precision for conditions such as diabetic retinopathy and retinal vein occlusion.

LYNX offers a compact, wearable laser treatment solution that integrates with a slit lamp, making it easier for physicians to use in various clinical settings. The device’s portability and ease of use could make laser therapy more accessible, benefiting both practitioners and patients by streamlining retinal laser treatments.

?? What makes this laser system stand out? Get the details

5. Research Links Retinal Imaging to Improved Schizophrenia Detection

A new study has found a correlation between retinal imaging and the early detection of schizophrenia. Researchers discovered that retinal biomarkers could provide insights into neurodegenerative processes associated with the condition.

The study indicates that certain retinal changes, such as vascular abnormalities and structural thinning, may serve as early indicators of schizophrenia. Using retinal scans for mental health diagnostics could enable earlier intervention, helping patients receive treatment before symptoms worsen. This breakthrough could bridge the gap between ophthalmology and neurology, demonstrating the eye’s role as a window to brain health.

?? Could eye exams become a tool for mental health diagnosis? Read the study

6. Seabelife Reports Promising In Vivo Results for SBL03 Ophthalmic Gel

Seabelife has announced encouraging in vivo results for SBL03, an ophthalmic gel designed to protect corneal cells from oxidative damage. The therapy is being developed for treating severe ocular surface disorders, such as chemical burns and dry eye disease.

The preclinical studies showed that SBL03 effectively reduced oxidative stress-induced damage in corneal cells, promoting faster healing and improved cell survival. If clinical trials confirm its efficacy, SBL03 could become a valuable new option for treating corneal injuries and preventing long-term damage caused by oxidative stress.

?? What’s next for this innovative treatment? Learn more

Stay Updated: For more insights on the latest developments in ophthalmology, visit our website and follow us for regular updates.

Thank you for staying connected with OBN!

Enjoy our LinkedIn updates? You can also stay updated with the latest news via email.

? Click here to subscribe and never miss a story!